Home/Resources/FDA enforcement tracker

UPDATED WEEKLY FROM FDA RECORDS · LAST RUN OCT 30, 2026

FDA enforcement tracker for peptide suppliers

The FDA added 17 foreign drug makers to its import alerts in the last 90 days, most of them in China (9) and India (5). This page tracks those additions, warning letters that mention peptides, and every supplier in this directory with an FDA action on record.

How to read this: import alerts 66-40 and 66-79 cover all drug makers, not only peptide companies. Each entry links to the FDA record; check the firm name and address before drawing conclusions about a supplier.
17Import alert additions, last 90 days
8Peptide warning letters, last 90 days
15Listed suppliers with an open FDA action
983Drug makers currently on the three alerts

Import alert additions by month

Nov 20252
Dec 20252
Jan 20268
Feb 20263
Mar 20269
Apr 20266
May 20262
Jun 202611
Jul 20268
Aug 20268
Sep 20267
Oct 20262

By the "date published" the FDA shows for each firm on 66-40, 66-79 and the drug entries of 66-41. A firm whose entry is revised may move to a later month.

Firms added to FDA import alerts, last 90 days

66-40: Drug GMP failures · 66-41: Unapproved drugs promoted in the US · 66-79: Refused FDA inspection or records

DateFirmAlert
Oct 27, 2026COHESION BIOTEC PRIVATE LIMITEDIndia66-40Drug GMP failures
Oct 1, 2026Nanjing Chengong Pharmaceutical Co., Ltd.China66-40Drug GMP failures
Sep 30, 2026Shenzhen Benliju Bio-Tech Co., Ltd.China66-40Drug GMP failures
Sep 25, 2026Naturo Aid Pharmaceutical Inc.Canada66-41Unapproved drugs promoted in the US
Sep 23, 2026Horster Biotek Private LimitedIndia66-79Refused FDA inspection or records
Sep 21, 2026Sanrace Biotechnology Co., Ltd.China66-40Drug GMP failures
Sep 19, 2026Chengdu Shengnuo Biopharm Co., Ltd.China66-40Drug GMP failures
Sep 15, 2026Jiangsu Grand Xinyi Pharmaceutical Co., LtdChina66-79Refused FDA inspection or records
Sep 3, 2026PRITAM INTERNATIONAL PRIVATE LIMITEDIndia66-40Drug GMP failures
Aug 28, 2026Aurolab TrustIndia66-40Drug GMP failures
Aug 26, 2026Chongqing Qiancan Technology Co., Ltd.China66-79Refused FDA inspection or records
Aug 25, 2026Tianjin Healthcare Medical Technology Co., LtdChina66-79Refused FDA inspection or records
Aug 14, 2026TSP Solutions Pte. Ltd.Singapore66-40Drug GMP failures
Aug 13, 2026Rohto-Mentholatum (Vietnam) Co., Ltd.Vietnam66-40Drug GMP failures
Aug 11, 2026Shoolin Pharma Chem LLPIndia66-40Drug GMP failures
Aug 7, 2026Guangdong Bangze Medicine Co., LtdChina66-40Drug GMP failures
Aug 4, 2026Zhejiang Jifu Daily Chemical Co., Ltd.China66-40Drug GMP failures

FDA warning letters mentioning peptides

Letters from the FDA drug center (CDER) about unapproved or misbranded drugs whose text names a peptide or research-use-only selling, posted in the last 12 months.

IssuedCompanyMentions
Sep 24, 2026Cheap Medicine Shop/www.cheapmedicineshop.comUnapproved New Drugs/Misbranded (Internet Pharmacy)semaglutide
Sep 23, 2026Online Generic Medicine/www.onlinegenericmedicine.comUnapproved New Drug/Misbranded (Internet Pharmacy)peptide, semaglutide, GLP-1
Sep 18, 2026Empower Clinic Services, LLC dba Empower PharmacyCGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drugsemaglutide, tirzepatide
Aug 24, 2026TXP Innovations LLC dba Tex PeptidesUnapproved New Drugs/Misbrandedpeptide, semaglutide, tirzepatide, retatrutide
Aug 24, 2026Royal Peptides LLCUnapproved New Drugs/Misbrandedpeptide, semaglutide, tirzepatide, retatrutide
Aug 24, 2026NuScience Peptides LLCUnapproved New Drugs/Misbrandedpeptide, semaglutide, retatrutide, survodutide
Aug 24, 2026Peptide Partners LLCUnapproved New Drugs/Misbrandedpeptide, semaglutide, tirzepatide, retatrutide
Aug 24, 2026Peak Performance PeptidesUnapproved New Drugs/Misbrandedpeptide, semaglutide, retatrutide, GLP-1

Listed suppliers with an FDA action on record

Each was matched by name and address to the FDA record before being added to its profile. An open action caps the supplier's confidence score; a closed one stays visible on the profile.

DateSupplierActionStatus
Sep 19, 2026Chengdu Shengnuo BiopharmChinaImport Alert 66-40Dayi County, Chengdu facility; all drugs and drug productsOpen
Sep 18, 2026Empower PharmacyUSA (TX)MARCS-CMS 738238CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New DrugOpen
Sep 18, 2026Curia GlobalGlobal320-26-127CGMP for APIs; Rensselaer, NY facility (Curia New York), incomplete HPLC/UPLC laboratory data; not confirmed as a peptide API siteOpen
Aug 24, 2026Peptide PartnersUSAMARCS-CMS 735063Unapproved New Drugs/MisbrandedOpen
Aug 24, 2026Royal PeptidesUSA / CanadaMARCS-CMS 734884Unapproved New Drugs/MisbrandedOpen
Aug 18, 2026Reliance Life SciencesIndia (Navi Mumbai)320-26-117CGMP, finished pharmaceuticals; Navi Mumbai facility, inaccurate microbiology laboratory recordsOpen
Jul 9, 2026Reliance Life SciencesIndia (Navi Mumbai)Import Alert 66-40Dhirubhai Ambani Life Sciences Centre, Navi Mumbai; all drugs and drug products manufactured by the companyOpen
Jun 2, 2026Zydus LifesciencesIndia (Ahmedabad)MARCS-CMS 722576CGMP, finished pharmaceuticals; Baddi, Himachal Pradesh facility, not a peptide API siteOpen
May 1, 2026Harbin Jixianglong BiotechChina (Harbin)Warning letterCGMP for APIs; relabeled semaglutide API from unapproved suppliersOpen
Feb 27, 2026Harbin Jixianglong BiotechChina (Harbin)Import Alert 66-40All drugs and drug productsOpen
Jan 16, 2026BiopeptekUSA (Malvern, PA)Import Alert 66-79Qingdao, Shandong facility; firm refused FDA inspection; all drugs and drug products. We have not confirmed which site makes Biopeptek peptide APIsOpen
Dec 8, 2025DarmericaUSA (FL)320-26-24CGMP for APIs, Davie, FL facility; distributed retatrutide and other unapproved peptide APIs for compounding, GLP-1 APIs received labeled as "custom peptide", sourced from a supplier not registered with FDAOpen
Dec 10, 2024Swiss ChemsUSA (NY)MARCS-CMS 695663Unapproved New Drugs/MisbrandedOpen
Aug 29, 2024Zydus LifesciencesIndia (Ahmedabad)MARCS-CMS 685224CGMP, finished pharmaceuticals; Jarod, Gujarat facility, not a peptide API siteClosed Dec 9, 2025
Jun 18, 2024Sun Pharmaceutical IndustriesIndia (Mumbai)MARCS-CMS 677337CGMP, finished pharmaceuticals; Dadra facility, not a peptide API siteOpen
Nov 17, 2023CiplaIndia (Mumbai)Warning letterPithampur, Madhya Pradesh finished-dose facility, not a peptide API siteOpen
Dec 7, 2022Sun Pharmaceutical IndustriesIndia (Mumbai)Import Alert 66-40Halol, Gujarat facility; Karkhadi listed since 2014 and former Ranbaxy sites at Paonta Sahib and Dewas since 2009; we have not confirmed which site makes its peptide APIsOpen
Feb 16, 2021Shilpa PharmaIndiaImport Alert 66-40Jadcherla, Telangana formulations facility, not confirmed as a peptide API siteOpen
Feb 12, 2020CiplaIndia (Mumbai)Warning letterGoa finished-dose facility, re-inspected and classed VAI in June 2024Open
Oct 8, 2013GL Biochem (Shanghai)ChinaImport Alert 66-41519 Zi Yue Road, Shanghai; cosmetics (FDA product code 53) under the alert for unapproved new drugs promoted in the US. Peptide APIs and research peptides are not named in the entryOpen

Sources and method

Import alert data is read every Thursday from the FDA red lists for Import Alert 66-40, Import Alert 66-41, Import Alert 66-79. Entries on 66-41 are limited to human drug products; its food and cosmetic entries are left out. Warning letters are read every Wednesday from the FDA warning letter database and kept when the letter text mentions a peptide or research-use-only selling.

A firm's presence here is the FDA's finding, not ours. To vet a specific manufacturer, use the GMP lookup tool or compare suppliers with a clean record on the top verified peptide suppliers list.

Frequently asked questions

What does an FDA import alert mean for a peptide buyer?

Products from a firm on an import alert can be detained at the US border without physical examination. For buyers, an import alert on a drug or API maker means shipments into the US are likely to be held, and on 66-40 it means the FDA found the firm did not meet drug GMP.

Is every firm on this page a peptide manufacturer?

No. Import alerts 66-40 and 66-79 cover all drug makers, so many entries make OTC drugs, cosmetics or supplements. Check each firm's FDA record to judge whether it matters for your supply chain. Warning letters are only included if the letter text mentions peptides.

How often is the tracker updated?

Weekly. Warning letters are checked every Wednesday and import alerts every Thursday, and the page rebuilds from the FDA lists automatically.

What happens when a listed supplier appears on an alert?

We check the firm name and address against the FDA record before changing anything. Once confirmed, the action is shown on the supplier's profile and caps its confidence score until the FDA closes it.